Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius Medical Care AG & Co. KGaA    FME   DE0005785802

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius Medical Care AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

share with twitter share with LinkedIn share with facebook
08/06/2020 | 06:20am EDT

DGAP Voting Rights Announcement: Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

06.08.2020 / 11:17
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Notification of Major Holdings

1. Details of issuer
Name: Fresenius Medical Care AG & Co. KGaA
Street: Else-Kröner-Straße 1
Postal code: 61352
City: Bad Homburg
Germany
Legal Entity Identifier (LEI): 549300CP8NY40UP89Q40

2. Reason for notification
X Acquisition/disposal of shares with voting rights
  Acquisition/disposal of instruments
  Change of breakdown of voting rights
  Other reason:

3. Details of person subject to the notification obligation
Legal entity: Artisan Partners Asset Management Inc.
City of registered office, country: Wilmington, Delaware, United States of America (USA)

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
 

5. Date on which threshold was crossed or reached:
03 Aug 2020

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
Total of both in %
(7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New 2.9998 % 0.00 % 2.9998 % 304607990
Previous notification 3.02 % 0.00 % 3.02 % /

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN Absolute In %
  Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
DE0005785802 0 9137481 0 % 2.9998 %
Total 9137481 2.9998 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
%
    Total %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
%
      Total %

8. Information in relation to the person subject to the notification obligation
  Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least 3% or more) % of voting rights through instruments (if at least 5% or more) Total of both (if at least 5% or more)
Artisan Partners Asset Management Inc. % % %
Artisan Partners Holdings LP % % %
Artisan Investments GP LLC % % %
Artisan Partners Limited Partnership % % %

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights Proportion of instruments Total of both
% % %

10. Other explanatory remarks:
 

Date
05 Aug 2020



06.08.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Internet: www.freseniusmedicalcare.com

 
End of News DGAP News Service

1111681  06.08.2020 

fncls.ssp?fn=show_t_gif&application_id=1111681&application_name=news&site_id=zonebourse
© EQS 2020

share with twitter share with LinkedIn share with facebook
All news about FRESENIUS MEDICAL CARE AG & CO. KGAA
09:27aFMC FRESENIUS MEDICAL CARE AG & CO K : Berenberg reiterates its Buy rating
MD
08:58aFMC FRESENIUS MEDICAL CARE AG & CO K : Receives a Buy rating from UBS
MD
08:24aFMC FRESENIUS MEDICAL CARE AG & CO K : Warburg Research sticks Neutral
MD
08:06aFRESENIUS SE : Warburg Research remains its Buy rating
MD
08:01aFRESENIUS SE : Barclays keeps its Buy rating
MD
07:45aFRESENIUS SE : Goldman Sachs remains its Buy rating
MD
07:15aFMC FRESENIUS MEDICAL CARE AG & CO K : Kepler Cheuvreux remains its Buy rating
MD
06:59aFMC FRESENIUS MEDICAL CARE AG & CO K : Bernstein reiterates its Neutral rating
MD
06:54aFRESENIUS SE : Bernstein keeps its Buy rating
MD
05:53aFMC FRESENIUS MEDICAL CARE AG & CO K : Goldman Sachs reiterates its Buy rating
MD
More news
Financials (USD)
Sales 2020 21 504 M - -
Net income 2020 1 548 M - -
Net Debt 2020 14 299 M - -
P/E ratio 2020 15,2x
Yield 2020 1,77%
Capitalization 23 422 M 23 437 M -
EV / Sales 2020 1,75x
EV / Sales 2021 1,64x
Nbr of Employees 124 736
Free-Float 65,1%
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 97,65 $
Last Close Price 79,99 $
Spread / Highest target 43,5%
Spread / Average Target 22,1%
Spread / Lowest Target -20,5%
EPS Revisions
Managers
NameTitle
Rice Powell Chairman-Management Board
Dieter Schenk Chairman-Supervisory Board
Helen Giza Chief Financial Officer
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer
Sector and Competitors